Flow cytometric analysis of human CD126 expression on human peripheral blood lymphocytes. Human peripheral blood lymphocytes were stained with Brilliant Violet 421™ Mouse Anti-Human CD3 Antibody and either Biotin IgG1, κ Isotype Control (left panel) or SDT Biotin Mouse Anti-Human CD126 Antibody (right panel) at 5μl/test followed by Sav-PE. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Biotin Mouse Anti-Human CD126 Antibody (S-2897)
Biotin Mouse Anti-Human CD126 Antibody (S-2897)
Price:
Regular price
$120 USD
Regular price
Sale price
$120 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD126 |
| Synonyms | Interleukin-6 receptor subunit alpha; IL-6 receptor subunit alpha; IL-6R subunit alpha; IL-6R-alpha; IL-6RA; IL-6R 1; Membrane glycoprotein 80 (gp80); IL6R |
| Location | Cell membrane |
| Accession | P08887 |
| Clone Number | S-2897 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | human peripheral blood lymphocytes |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD126, also known as the interleukin-6 receptor alpha chain (IL-6Rα), is a type I cytokine receptor that plays a crucial role in regulating cell growth and differentiation in various tissues. It is a subunit of the IL-6 receptor complex, which also includes the signal-transducing subunit glycoprotein 130 (gp130 or CD130). CD126 is primarily expressed on B cells, epithelial cells, and hepatocytes. The binding of IL-6 to CD126 forms a complex that, in association with CD130, initiates signaling pathways involved in immune responses and acute phase reactions. Dysregulated production of IL-6 and CD126 is implicated in the pathogenesis of several diseases, including multiple myeloma, autoimmune diseases, and certain cancers. Additionally, CD126 is being explored as a potential therapeutic target for CAR-T cell therapy due to its expression in various tumors.
Picture
Picture
FC
